Wilmington, Delaware — October 30, 2025 — Leads & Copy — Travere Therapeutics (NASDAQ: TVTX) reported positive Q3 2025 financial results, with U.S. net product sales at $113.2 million, driven by FILSPARI growth. Total revenue reached $164.9 million, including a $40.0 million milestone from CSL Vifor.
R&D expenses were $51.9 million, while SG&A expenses totaled $86.5 million. Net income was $25.7 million, or $0.29 per basic share. As of Sept. 30, 2025, cash, equivalents, and marketable securities totaled $254.5 million.
FILSPARI sales in the U.S. hit $90.9 million, a 155% year-over-year increase. The company received 731 new patient start forms and FDA approved a REMS modification for FILSPARI. KDIGO updated clinical practice guidelines to include FILSPARI for earlier use in IgAN.
Travere will present new IgAN and FSGS data at ASN Kidney Week 2025. The FDA is reviewing the sNDA for FILSPARI in FSGS, with a target action date of Jan. 13, 2026. Pegtibatinase commercial-scale batches have been manufactured, with plans to restart the HARMONY Study in 2026.
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics.
Contact:
Source: Travere Therapeutics, Inc.
